Announcements Trials
Browse Landscape

Phase

Phase 2 112Phase 3 59Phase 1/2 19Phase 1 17Phase NA 6Phase 4 6Phase 2/3 5Phase EARLY_PHASE1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Letrozole 9Fluorodeoxyglucose F18 7pembrolizumab 6Magnetic Resonance Spectroscopy 6atezolizumab 5Blood Specimen Collection 5Trastuzumab 4Oncolytic Virotherapy 4Biopsy 4Bevacizumab 4palbociclib 3durvalumab 3Vitamin D 3Taxes 3Saline Solution 3Radiotherapy 3Metformin 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Albumin-Bound Paclitaxel 3pertuzumab 2olaparib 2bazedoxifene 2Vinorelbine 2Tamoxifen 2Sentinel Lymph Node Biopsy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × pertuzumab × Breast × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01875666 2020-09-04

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
26 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡